. 2025 Aug 18;9:e2500033. doi: 10.1200/PO-25-00033

TABLE 1.

Genomic Dynamics in Gene Alterations at Each Time Point

Specimen	Pre-Pemigatinib (6 weeks before pemigatinib)		PR Post-Pemigatinib (2 weeks after peimigatinib)		PD Post-Pemigatinib (8 weeks after pemigatinib)		PD Post-Erdafitinib (13 weeks after pemigatinib)
Liquid	Caris Assure		Caris Assure		Guardant360		Guardant360
	Amplification	pCN	Amplification	pCN	Amplification	pCN	Amplification	pCN
	FGFR2	16.6	FGFR2	5.2	FGFR2	110.1	FGFR2	34.3
	Mutation	VAF	Mutation	VAF	MYC	45.4	MYC	11.2
	CDH1, L214P	46	CDH1, L214P	0.6	KRAS	3.0	KRAS	ND
	FGFR2, C382R	0.1	CDH1, W409*	0.6	Mutation	VAF	Mutation	VAF
					FGFR2, L617V	8.4	FGFR2, L617V	7.4
					FGFR2, E565A	7.1	FGFR2, E565A	11.6
					FGFR2, V564L	2.3	FGFR2, V564L	6.6
					FGFR2, N549H	0.8	FGFR2, N549H	1.1
					FGFR2, N549K	0.7	FGFR2, N549K	0.8
					FGFR2, V564F	0.2	FGFR2, V564F	0.2
					Fusion		FGFR2, V564I	0.3
					FGFR2-PRNCR1	0.08	FGFR2, E565G	1.3
							FGFR2, N549D	0.7
							FGFR2, E565K	0.6
							TP53, E339fs	12.5
							Fusion
							FGFR2-PRNCR1	0.05
Tissue^a	MI Profile
	Amplification	CN
	FGFR2	264
	Mutation	VAF
	CDH1, L214P	58
	SMAD4, E330K	44
	TP53, E339fs	46

Abbreviations: CN, copy number; FGFR, fibroblast growth factor receptor; ND, not detected; PD, progressive disease; pCN, plasma CN; PR, partial response; VAF, variant allele frequency.

^{^a}

Tumor tissue resected at surgery.